InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine solutions becomes feasible and highly...

InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration GUILFORD, Conn. and TOKYO, May 31, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug and target discovery...

InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...